anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A tumour-inhibiting polysaccharide, viscic acid, or salts thereof is extracted from plant material of viscum album or Loranthus species, especially L. europeus L. The novel polysaccharide has a pK acid value of 3,9 (C=1,1x10-2 equivalents/l) and a specific rotation of [a ]25= -26,7 DEG \sB1 DEG . The molecule is composed of galactose, arabinose, rhamnose and a uronic acid, possibly glucuronic acid. The ultra-violet spectrum contains no absorption bands, while the infra red spectrum shows maxima (in mm ) at 2,95-3,00 5,74 6,08, and a shoulder at 7,2 with a maximum at 8,00-8,05. Viscic acid is isolated by extracting the plants with water, or by expressing the juice, followed by dialysis of extract or juice. The undialysable portion, is advantageously concentrated or freeze-dried to yield a plant extract enriched in viscic acid or salts thereof. Pure, free viscic acid or salts thereof may be isolated by, e.g. fractional precipitation with water-miscible organic solvents, particularly ethanol, optionally in presence of absorbents or strong electrolytes by electrophoresis or by precipitating contaminants with a quaternary ammonium compound, e.g. cetyl trimethylammonium chloride, followed by dialysis and freeze-drying. Ammoniumsalts may also be used to precipitate viscic acid in presence of a borate buffer of pH 10. Free viscic acid may be obtained from salts by, e.g. cation exchange, or dialysis against dilute acid. Viscic acid or salts thereof may be used for treatment of cancer diseases, e.g. in conjunction with pharmaceutical organic or inorganic vehicles. The pharmaceutical preparation may be in the form of dry ampoules which may contain preserving, stabilizing, wetting or emulsifying agents.ALSO:Pharmaceutical preparations contain viscic acid, a tumour-inhibiting polysaccharide isolated from Viscum album (mistletoe) or Loranthus species, e.g. Loranthus europeus L. (Group IV (a)). The preparations may comprise viscic acid and/or a salt thereof in admixture of conjunction with an inorganic or organic carrier suitable for parenteral administration. The preparations may be in the form of dry ampoules and may be sterilized and may contain preserving, stabilizing, wetting or emulsifying agents, salts for regulating osmotic pressure, buffers or other therapeutically active substances. The active substance may be recovered from the non-dialysable portion of an aqueous extract or the expressed juice of plants of the Viscum Album (mistletoe) or Loranthus species.
See FDA-approved patient labeling (Patient Information)

Dosing and Administration

Instruct patients to swallow INTUNIV whole with water, milk or other liquid. Patients should not take INTUNIV together with a high-fat meal, since this can raise blood levels of INTUNIV . Instruct the parent or caregiver to supervise the child or adolescent taking INTUNIV and to keep the bottle of tablets out of reach of children. ®Tablets should not be crushed, chewed or broken prior to administration because this may increase the rate of release of the active drug .®®®

Instruct patients on how to properly taper the medication, if the physician decides to discontinue treatment. [ ]. see Dosage and Administration (2.5)

Adverse Reactions

Advise patients that sedation can occur, particularly early in treatment or with dose increases. Caution against operating heavy equipment or driving until they know how they respond to treatment with INTUNIV Headache and abdominal pain can also occur. If any of these symptoms persist, or other symptoms occur, the patient should be advised to discuss the symptoms with the physician. ®[ ]. see Warnings and Precautions (5.2)

Advise patients to avoid becoming dehydrated or overheated, which may potentially increase the risks of hypotension and syncope Advise patients to avoid use with alcohol. [ ]. see Warnings and Precautions (5.1)
A computer implemented system and method for matching drugs and diseases and generating a weighted relationship between the matched drugs and diseases. The system stores a quantity of patient medical history billing records identifiable as patient prescription claim records and medical claim records. The system also stores a grouping of drug codes and groupings of diagnosis codes. The system is configured to match drugs identified in a specific patient's prescription claim records with diseases identified in the patient's medical claims. The system generates a weighted relationship between the matched drugs and diseases by calculating a link weight in accordance with a preprogrammed formula for each occurrence of the diagnosis codes identified in the patient's medical claims that is identified as associated with the disease identified and the drug upon which the query is being processed. The link weight provides a statistical match association value to each of the matched diseases.
OBJECTIVE: Gastric cancer (GC) is believed to be one of the most common digestive tract malignant tumors. However, mounting evidence indicates a link between the glycolysis and tumorigenesis, including gastric cancer.
METHODS: Our research identified 5508 differently expressed mRNAs in gastric cancer. Then, the genes highly associated with tumorigenesis were identified through weighted correlation network analysis (WGCNA). Bioinformatics analysis observed that these hub genes were significantly linked to the regulation of cell cycle, drug metabolism, and glycolysis. Among these hub genes, there is a critical gene involved in glycolysis regulation, namely fructose-bisphosphate B (ALDOB).
RESULTS: Analysis based on The Cancer Genome Atlas (TCGA) and three Gene Expression Omnibus (GEO) datasets revealed that ALDOB was significantly downregulated in GC compared with normal tissues. In addition, cell viability assay confirmed that ALDOB acted as a tumor suppressor. Finally, drug sensitivity analysis revealed that ALDOB increased the sensitivity of gastric cancer cells to most antitumor drugs, especially talazoparib, XAV939, and FTI-277. Our results showed that the expression of ALDOB was significantly lower in GC tissues than in normal tissues. And ALDOB significantly inhibited proliferation and migration, delayed glycolysis in GC cells. Consequently, our study suggests that ALDOB may be a potential target for the clinical treatment of gastric cancer.
A two-phase (dose response preceded by a breath hydrogen phase) double-blind, multi-site, crossover trial was conducted in 28 pediatric patients (approximately 5 months to 12 years of age) with confirmed CSID. During the dose response phase, the patients were challenged with an ordinary sucrose-containing diet while receiving each of four doses of sacrosidase: full strength (9000 I.U./mL) and three dilutions (1:10 [900 I.U./mL], 1:100 [90 I.U./mL], and 1:1000 [9 I.U./mL]) in random order for a period of 10 days. Patients who weighed no more than 15 kg received 1 mL per meal; those weighing more than 15 kg received 2 mL per meal. The dose did not vary with age or sucrose intake. A dose-response relationship was shown between the two higher and the two lower doses. The two higher doses of sacrosidase were associated with significantly fewer total stools and higher proportions of patients having lower total symptom scores, the primary efficacy end-points. In addition, higher doses of sacrosidase were associated with a significantly greater number of hard and formed stools as well as with fewer watery and soft stools, the secondary efficacy end-points.

Analysis of the overall symptomatic response as a function of age indicated that in CSID pediatric patients up to 3 years of age, 86% became asymptomatic. In pediatric patients over 3 years of age, 77% became asymptomatic. Thus, the therapeutic response did not differ significantly according to pediatric age.

A second study of similar design and execution as the first used 4 different dilutions of sacrosidase: 1:100 (90 I.U./mL), 1:1000 (9 I.U./mL), 1:10,000 (0.9 I.U./mL), and 1:100,000 (0.09 I.U./mL). There were inconsistent results with regards to the primary efficacy parameters.

In both trials, however, pediatric patients showed a marked decrease in breath hydrogen output when they received sacrosidase in comparison to placebo.

The effects of Sucraid have not been evaluated in patients with secondary (acquired) sucrase deficiency.
Ointments contg. 2% nitroglycerine are new. The medicament is pref. contained in 80g tubes fitted with a dosing applicator giving a dose of 15g nitroglycerine. The normal admin. dosage is 7.5-30mg nitroglycerine, 3-6 times daily. The ointment is applied to the anterior thoracic or thoraco-abdominal region in an area 15cm2. The ointment is well tolerated. As with other administrations of nitroglycerine, headaches occur which disappear or decrease after 2-3 days. There was no evidence of haematological, renal, or hepatic intolerance. Percutaneous treatment of coronary and cardiac insufficiency, including those associated with left ventricular insufficiency, and myocardial infarction.
PURPOSE: Management of scrotal hernias presents as a common challenge, with operative interventions to address these hernias associated with higher rates of morbidity compared to those of less-complex pathology. Surgeons have advocated for the use of techniques such as primary abandonment of the distal sac as a potential means to reduce complications for operative intervention, with preliminary findings demonstrating feasibility. We sought to assess outcomes related to primary sac abandonment among patients undergoing minimally invasive (MIS) repair of scrotal hernias.
METHODS: A review of prospectively maintained databases among two academic hernia centers was conducted to identify patients who underwent MIS inguinal hernia repairs with primary sac abandonment. Patient demographics, hernia risk factors, intraoperative factors, and postoperative outcomes were evaluated. Short-term outcomes related to patient-reported experiences and surgical-site occurrences requiring procedural intervention were queried.
RESULTS: Sixty-seven male patients [median age: 51.6 years; interquartile range (IQR): 45-65 years] underwent inguinal hernia repair with primary sac abandonment. Anatomic polypropylene mesh was used in 98.5% cases. Rates of postoperative complications were low and included postoperative urinary retention (6%), clinically identified or patient-reported seromas/hematomas within a 30-day follow-up period (23.9%), deep venous thrombosis (1.5%), and pelvic hematoma (1.5%). No seromas or hematomas necessitated procedural interventions, with resolution of symptoms within three months of their operation date.
CONCLUSION: We report a multi-center experience of patients managed with primary abandonment of the sac technique during repair of inguinoscrotal hernias. Utilization of this technique appears to be safe and reproducible with a low burden of short-term complications.
Participants randomized to the metformin arm of the study will receive this medication from months 1 through 12 after randomization. Subjects will receive 850 mg daily for 1 month and increase to 850 mg twice daily thereafter if no side effects are experienced.
In patients who come for treatment and have a prior appointment, an intraoral examination is performed using visual and tactile examination methods. A total of 639 proximal surfaces of 22 patients are examined by investigators using the visual-tactile method.
Intervention group (Mindfulness Smoking cessation program): Women in intervention group will be provided 2 sessions mindfulness training within 2 weeks. Each session will last for 2 hours with 8-20 participants. For mindfulness training, it aims to understand women smokers' own life planning, stressors and their correlation with smoking; to help women smokers sit with negative affect and alleviate stress through mindfulness; to educate women smokers gain the self-control and replace the smoking habit; to teach women smokers how to prevent craving and relapse.
The invention relates to a cellular protein which is specific and has high affinity for nucleic acid sequences characteristic of an intact TAR RNA loop sequence of the HIV LTR TAR region. The invention also relates to a between 1,000-10,000-fold purified, about 185 kD protein preparation isolated from a mammalian cell nuclear extract preparation, most specifically a HeLa cell extract. The about 185 kD protein is shown to regulate HIV viral gene expression by binding a TAR RNA region of an HIV LTR template, in the presence of a cofactor fraction (including at least a˜100 kD cofactor), and a tat protein. The TRP-185, having a molecular weight of about 185 kD protein may also provide a research tool in the study of viral and cellular gene expression. A route for the development of immunodiagnostics for AIDS and related disorders may also be provided given the specific and high affinity of TRP-185 for HIV RNA. The 185 kD protein and related encoding amino acid and DNA sequences may also be used in therapeutic agents for AIDS and related disorders and, for the generation of specific antibodies for use in the diagnosis and study of the epidemiology of AIDS.
A portable, battery-powered per-patient device automatically detects and logs patient encounters with items, such as medical equipment, drug containers, caregivers, visitors and other patients, in a healthcare facility. A separate per-patient device is assigned to each patient in the facility. The per-patient device is intended to remain with the patient during the patient's stay. The device may be attached to the patient's bed, wheelchair, walker or the like. If the patient is ambulatory, the patient may carry the device. RF-ID or other suitable tags are attached to items that a patient may encounter. Each per-patient device automatically detects and logs RF-ID-tagged items, including the patient, that come within a range of the device. The device also detects and longs when an item is no longer within range of the device, such as because a caregiver leaves the patient's room or a medical device is removed from the patient's room. The per-patient device also detects and logs when an item is reunited with a patient. Information, such as a time and date on which an RF-ID tag is detected or ceases to be detected, may be included in the log. The logged information may be used to obtain status or location information about the items. In addition, if an item or a patient is found to be infected, all the people or items that encountered the item or patient can be listed by querying the log.
Customized therapeutics and in situ diagnostics for patient therapy and diagnosis takes advantage of tools including techniques for derivatizing colloids with self-assembled monolayers. This provides the capability of a wide variety of assays including chemical or biochemical agent/agent interaction studies. Bio-derivatized colloids, with or without signaling entities, are used to probe interactions with species on non-colloidal structures. The invention provides techniques for immobilizing colloidal particles on a wide variety of non-colloidal structures. Included is the ability to decorate a variety of non-colloidal structures including beads, with colloids as a detectable assay. This allows, in many cases, assays detectable via the unaided human eye, as well as assays detectable via automated determination of a change of interaction of electromagnetic radiation with the colloids, e.g., absorption, light-scattering, and the like.
Mode of Action

Alprostadil is a smooth muscle relaxant. Precontracted isolated preparations of the human corpus cavernosum, corpus spongiosum and cavernous artery are relaxed by alprostadil. Alprostadil has been shown to bind to specific receptors in human penile tissue. Two types of receptors that differ in their PGE1 binding affinity have been identified. The binding of alprostadil to its receptors is accompanied by an increase in intracellular cAMP levels. Human cavernous smooth muscle cells respond to alprostadil by releasing intracellular calcium into the surrounding medium. Smooth muscle relaxation is associated with a reduction of the cytoplasmic free calcium concentration. Alprostadil also attenuates presynaptic noradrenaline release in the corpus cavernosum which is essential for the maintenance of a flaccid and non-erect penis.

Alprostadil induces erection by relaxation of trabecular smooth muscle and by dilation of cavernous arteries. This leads to expansion of lacunar spaces and entrapment of blood by compressing the venules against the tunica albuginea, a process referred to as the corporal veno-occlusive mechanism.
Children enrolled in the trial will be randomized to either the azithromycin, amoxicillin, or placebo arm. Children randomized to the azithromycin arm will receive all standard severe acute malnutrition (SAM) outpatient treatment per Burkinabe national guidelines, except that the standard amoxicillin treatment will be changed to azithromycin. Children will receive a directly observed dose of azithromycin (20 mg/kg, single directly observed dose, oral suspension), followed by a 7-day course of placebo (administered at 80 mg/kg, split into 2 daily doses for 7 days, oral suspension).
Impaired sensorimotor functions are prominent complications of spinal cord injury (SCI). A clinically important but less obvious consequence is development of metabolic syndrome (MetS), including increased adiposity, hyperglycemia/insulin resistance, and hyperlipidemia. MetS predisposes SCI individuals to earlier and more severe diabetes and cardiovascular disease compared to the general population, which trigger life-threatening complications (e.g., stroke, myocardial infarcts). Although each comorbidity is known to be a risk factor for diabetes and other health problems in obese individuals, their relative contribution or perceived importance in propagating systemic pathology after SCI has received less attention. This could be explained by an incomplete understanding of MetS promoted by SCI compared with that from the canonical trigger diet-induced obesity (DIO). Thus, here we compared metabolic-related outcomes after SCI in lean rats to those of uninjured rats with DIO. Surprisingly, SCI-induced MetS features were equal to or greater than those in obese uninjured rats, including insulin resistance, endotoxemia, hyperlipidemia, liver inflammation and steatosis. Considering the endemic nature of obesity, we also evaluated the effect of premorbid obesity in rats receiving SCI; the combination of DIO + SCI exacerbated MetS and liver pathology compared to either alone, suggesting that obese individuals that sustain a SCI are especially vulnerable to metabolic dysfunction. Notably, premorbid obesity also exacerbated intraspinal lesion pathology and worsened locomotor recovery after SCI. Overall, these results highlight that normal metabolic function requires intact spinal circuitry and that SCI is not just a sensory-motor disorder, but also has significant metabolic consequences.
The invention relates to a CNTF (ciliary neurotrophic factor) mutant and a modified mutant and an application thereof. The CNTF mutant is prepared by mutating on the basis of an amino acid sequence of natural CNTF. The mutation comprises: lysine at the 40th locus is mutated into cysteine, and cysteine at the 17th locus is mutated into alanine. According to the CNTF mutant disclosed by the invention, the modified CNTF with high modification specificity can be obtained, so that the problems that the modified products are non-uniform and the result is unstable due to modification and the like are solved. Moreover, the recombinant CNTF protein structure is stable. Compared with natural proteins, the CNTF protein has high biological activity and solubility, and the modified CNTF has a long-acting effect compared with non-modified CNTF.
Materials and Methods: study is a mixed-method approach with a qualitative and pre-test post-test design, utilizing randomized controlled quasiexperimental type. The research was conducted with mothers of infants diagnosed with congenital heart disease who sought care at the Pediatric Cardiology Outpatient Clinic of a university hospital and were followed up. There are two groups in the study. Web-based education was provided to mothers in the intervention group (n=30). No intervention was applied to the mothers in the control group (n=30) other than the outpatient clinic routine of the hospital. "Qualitative interview form, Parent-infant Introductory Information Form, Quality of Life Scale and Generalized Perceived Self-Efficacy Scale" were used. The research process had two stages; in the first stage, qualitative data was collected and after qualitative interviews with mothers, the content of the web-based training was created in line with the needs of the mothers. In the second stage, quantitative data were collected, and a web-based training program was applied to the intervention group and an outpatient clinic routine to the control group.
Halogenated 3,4-benzpyrenes are prepared by diluting with an inert solvent (such as benzene, toluene, xylene or chloroform) a coal-tar fraction boiling above 450 DEG  C. enriched with 3,4-benzpyrene, treating the solution with a halogen at 5-30 DEG  C., and filtering or centrifuging the halo-3,4-benzpyrene.  The product may be further halogenated in a solvent at 30-70 DEG  C. The preferred halogens are chlorine and bromine.ALSO:A substance for impregnating wood comprises the residue obtained by halogenating a solution of a coal tar fraction boiling above 450 DEG C. enriched in 3,4-benzpyrene, removing the halo-3,4-benzpyrene product by filtering or centrifuging, and partially or completely removing solvent from the residue (see Division C2).  The residue may be used in solution in benzene, crude benzene, chloroform, chlorobenzene, or impregnating oil.ALSO:A substance for improving the aspect of and providing an impregnant for surfaces of wood, metal and stone comprises the residue obtained by halogenating a solution of a coal tar fraction boiling above 450  DEG C. enriched in 3,4-benzpyrene, removing the halo-3,4-benzypyrene product by filtering or centrifuging, and partially or completely removing solvent from the residue (see Division C2).  This residue, or its solution in e.g. benzene, crude benzene, chloroform, chlorobenzene or impregnating oil provides a lacquer, paint or impregnant for dripping, spraying or brushing on wood, metal or stone.  The solutions also have bactericidal and fungicidal properties.
Tuberculin is prepared by a process characterized by entraining tuberculinic substances from filtered cultures of the bacilli by a precipitate of an acid in the nascent state, formed at pH 2.3-3.5. Thus, sodium salicylate, sodium para-aminosalicylate, sodium para-aminobenzoate or sodium borate may be dissolved in the culture medium, and the corresponding acid precipitated by the addition of hydrochloric acid.  The precipitate is dissolved in an organic solvent, e.g. acetone, which precipitates the tuberculinic substances.  The latter are dissolved in water, the pH is brought to 6.5-8 by sodium bicarbonate, and tuberculin is then precipitated by another organic solvent, e.g. alcohol.  It is washed with alcohol, then with acetone, and dried under vacuum.